Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

NCT01712308 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Anemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelofibrosis

Interventions

BIOLOGICAL: Sotatercept
DRUG: Ruxolitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]